Vanutide cridificar and the QS-21 Adjuvant in Japanese subjects with mild to moderate Alzheimer’s disease: Results from two phase 2 studies

Current Alzheimer Research

Volumn 12, Issue 3, 2015, Pages 242-254

  Arai, Heii ^a   Suzuki, Hideo ^b   Yoshiyama, Tamotsu ^b  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b PFIZER INC   (United States)

Author keywords

Alzheimer s disease; Amyloid plaques; Amyloid beta; Antibody; Immunotherapy; Vaccine

Indexed keywords

PHOSPHATE BUFFERED SALINE; QS 21; VANUTIDE CRIDIFICAR; AMYLOID BETA PROTEIN; ANTIBODY; HYBRID PROTEIN; IMMUNOLOGIC FACTOR; SAPONIN;

ABNORMAL LABORATORY RESULT; AGED; ALZHEIMER DISEASE; ANTIBODY TITER; ARTICLE; BACKACHE; BRAIN HEMORRHAGE; CATARACT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CONTUSION; DECREASED APPETITE; DELIRIUM; DENTAL CARIES; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLICULITIS; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; JAPANESE (PEOPLE); MALE; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; VOMITING; ADVERSE DRUG REACTION; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; IMMUNOLOGY; JAPAN; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; JAPAN; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECOMBINANT FUSION PROTEINS; SAPONINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928991840     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150302154121     Document Type: Article

References (27)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580): 353-6 (2002).
2. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al.Mutation of the β-amyloid precursor protein in familial Alzheimer’s disease increases β-protein production. Nature 360(6405): 672-4 (1992).
3. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al.Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2(8): 864-70 (1996).
4. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al.Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3(1): 67-72 (1997).
5. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al.Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330(6012): 1774 (2010).
6. Holtzman DM, Morris JC, Goate A. Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3(77): 77sr1 (2011).
7. Selkoe DJ. Resolving controversies on the path to Alzheimer’s therapeutics. Nat Med 17(9): 1060-5 (2011).
8. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. The Tacrine Study Group. JAMA 271(13): 985-91 (1994).
9. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 50(1): 136-45 (1998).
10. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289(2): 210-6 (2003).
11. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 44(1): 181-93 (2004).
12. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6(2): 108-19 (2010).
13. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al.Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400(6740): 173-7 (1999).
14. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al.Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8): 916-9 (2000).
15. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al.A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408(6815): 979-82 (2000).
16. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al.A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408(6815): 982-5 (2000).
17. Schenk D. Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci 3(10): 824-8 (2002).
18. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al.Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1): 46-54 (2003).
19. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9): 1553-62 (2005).
20. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4): 448-52 (2003).
21. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimer’s disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 5(3-4): 194-6 (2008).
22. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al.Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15(4): 505-14 (2003).
23. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al.Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomized, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11(7): 597-604 (2012).
24. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al.Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 7(4): 367-85 (2011).
25. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al.Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73(24): 2061-70 (2009).
26. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, et al.A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24(2): 198-203 (2010).
27. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al.Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11(3): 241-9 (2012).